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Background: VKORC1 has been identified some years ago as the gene encoding vitamin K epoxide reductase
(VKOR) – the target protein for coumarin derivates like warfarin or phenprocoumon. Resistance against warfarin and
other coumarin-type anticoagulants has been frequently reported over the last 50 years in rodents due to problems
in pest control as well as in thrombophilic patients showing variable response to anticoagulant treatment. Many
different mutations have already been detected in the VKORC1 gene leading to warfarin resistance in rats, mice and
in humans. Since the conventional in vitro dithiothreitol (DTT)-driven VKOR enzymatic assay often did not reflect the
in vivo status concerning warfarin resistance, we recently developed a cell culture-based method for coexpression
of VKORC1 with coagulation factor IX and subsequent measurement of secreted FIX in order to test warfarin inhibition
in wild-type and mutated VKORC1.
Results: In the present study, we coexpressed wild-type factor IX with 12 different VKORC1 variants which were
previously detected in warfarin resistant rats and mice. The results show that amino acid substitutions in VKORC1
maintain VKOR activity and are associated with warfarin resistance. When we projected in silico the amino acid
substitutions onto the published three-dimensional model of the bacterial VKOR enzyme, the predicted effects
matched well the catalytic mechanism proposed for the bacterial enzyme.
Conclusions: The established cell-based system for coexpression of VKORC1 and factor IX uses FIX activity as an
indicator of carboxylation efficiency. This system reflects the warfarin resistance status of VKORC1 mutations from
anticoagulant resistant rodents more closely than the traditional DTT-driven enzyme assay. All mutations studied
were also predicted to be involved in the reaction mechanism.
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Coagulation factor IXBackground
Vitamin K hydroquinone is an essential cofactor for the
posttranslational modification of vitamin K-dependent
(VKD) proteins by the endoplasmic membrane enzyme
γ-glutamyl-carboxylase (GGCX) [1]. VKD proteins com-
prise clotting factors II, VII, IX and X, protein C, S and
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reproduction in any medium, provided the orarrest-specific protein (gas6) and four transmembrane
proteins (PRGP1, PRGP2, TMG3, TMG4) [2,3]. For these
proteins, γ-carboxylation is essential in order to attain
their full biological activity state. During each carboxyl-
ation step, vitamin K hydroquinone is oxidised to vitamin
K epoxide which is in turn reduced by vitamin K epoxide
reductase (VKOR) [4]. The gene encoding vitamin K
epoxide reductase complex subunit 1 (VKORC1) was iden-
tified in 2004 by two independent working groups [5,6].
VKOR activity can be effectively inhibited by coumarin
derivatives such as warfarin or phenprocoumon. InhibitionLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Müller et al. BMC Genetics 2014, 15:17 Page 2 of 7
http://www.biomedcentral.com/1471-2156/15/17of VKOR leads to the secretion of under-carboxylated
VKD clotting factors and therefore to reduced blood
coagulation [7]. Coumarin derivatives are in world-wide
use for prevention and therapy of thromboembolic con-
ditions in humans and in higher doses as rodenticides.
Resistance in rats and mice has been reported first for
warfarin in 1960 [8,9] and some years later even for
more potent anticoagulants [10,11] leading to serious
local problems in pest control. Warfarin resistance has
also been demonstrated in patients suffering from
thromboembolic diseases who failed to respond to oral
anticoagulant treatment [12,13].
To date, many different point mutations have been
discovered in the VKORC1 gene of warfarin-resistant
rats and mice [14-16] as well as in humans [5,13,17]. In
house mice (Mus musculus domesticus), vkorc1 mutations
have not solely occurred spontaneously and positively
selected by anticoagulant rodenticides but can also ori-
ginate from the less warfarin-sensitive Mus spretus by
“adaptive introgressive hybridization” (interspecific mating
followed by introgression and selection on these alleles)
[18]. In rats, several vkorc1 mutations could be confirmed
as warfarin resistance-mediating by in vivo and in vitro
tests so far, while some variants were interpreted as
natural interspecies differences, e.g. between Rattus
norvegicus and Rattus rattus [19].
Upon site-directed mutagenesis in a VKORC1-cDNA
construct, only mutations at tyrosine-139 showed distinct
resistance to warfarin in an in vitro DTT-driven enzymatic
assay for VKOR activity [14]. Since this standard VKOR
assay could not clearly demonstrate warfarin resistance
for most VKORC1 mutations, a cell culture-based coex-
pression system was recently developed by our group [20].
In this system, a bicistronic vector harbouring human
VKORC1 and coagulation factor IX (FIX) cDNAs is
transfected into mammalian cells. In combination with
the endogenous carboxylase activity of these cells, the
concomitant expression of VKORC1 and FIX allows to
study the effects of mutations in the VKORC1 gene on
the activity of the clotting factor, the end product of γ-
carboxylation, and its inhibition by warfarin. The results
from this cell-based assay accurately reflect the warfarin
resistance phenotypes for three human VKORC1 muta-
tions identified in anticoagulant insensitive patients [20].
In the present study, the coexpression system was used
to study the effect of 12 different VKORC1 variants de-
tected in rats and mice on the production of clotting
factor IX in HEK 293 cells and its sensitivity to warfarin
inhibition. In contrast to the DTT-driven enzymatic
in vitro assay, in the cell-based assay mutations other
than those affecting position 139 of VKORC1 showed
resistance against warfarin. This is in good agreement
with the observation of in vivo resistance to warfarin
in rodents carrying such mutations. An in silico 3Dmodelling of the 12 amino acid substitutions into
mammalian VKORC1 (based on the recently published
structure of the bacterial homolog [21]) confirmed the
relevance of these amino acids which are substituted
in warfarin-resistant rodents with regard to protein
structure and binding of ligands like vitamin K, ubi-
quinone or coumarin derivatives.
Methods
Cloning and mutagenesis
The bicistronic vector for VKORC1 and FIX coexpression
was constructed by cloning FIX cDNA [GenBank: NM_00
0133] into a pCEP4 vector (Invitrogen, Karlsruhe, Germany)
using 5′ Nhe I and 3′ Xho I restriction sites and inserting
VKORC1 cDNA [GenBank: NM_024006] together with an
IRES sequence (internal ribosome entry site) downstream
from the FIX cDNA using 5′ Sfi I and 3′ Bgl II sites.
Site-directed mutagenesis was performed using the Quik-
Change mutagenesis kit (Stratagene, Amsterdam, NL)
following the manufacturer’s instructions. Mutagenic
primer pairs were about 30 base pairs in length and
flanked the desired mutation position (primer sequences
available on request).
Cell culture and protein expression
The bicistronic vector constructs were transfected into HEK
293 EBNA cells (Invitrogen, Karlsruhe, Germany) using
FuGene HD (Roche) and transfected cells were treated with
different concentrations of warfarin (0, 0.01, 0.03, 0.1 or
0.3 μM final conc.) as described by Fregin et al. [20]. Super-
natants of cell cultures containing secreted FIX were har-
vested after culturing for approx. 70 hours and concentrated
by ultrafiltration (10,000 MWCO; Vivaspin 6, Sartorius
Stedim Biotech S.A., France) after a short centrifugation step
to remove floating cells according to the manufacturer’s
conditions. Concentrates were resuspended in 800 μL
Owren Veronal buffer (Dade Behring, Siemens Healthcare
Diagnostics, Germany). Whole protein amounts of aliquots
of each concentrate were determined relative to a BSA
standard curve using the DC Protein Assay kit (BioRad,
Germany) according to the manufacturer’s instructions.
FIX activities of concentrated supernatants were deter-
mined after adding aliquots of 10 μl to factor-depleted
standard plasma (Siemens Healthcare Diagnostics Inc.,
Germany) using an Electra 1400c coagulometer (Instru-
mentation Laboratory). Standard pooled blood donor
plasma (Siemens Healthcare Diagnostics Inc., Germany)
served as a control. The activity of standard plasma was
set to 100% activity for FIX and sample activities were
normalized to this value.
2D and 3D protein structure analysis of VKORC1 variants
The three-dimensional model of wild-type mammalian
vitamin K epoxide reductase was constructed in silico by
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6869) in the 3D crystal structure of the bacterial homolog
of vitamin K epoxide reductase from Synechococcus sp.
(PDB-3KP9; [21]) using SWISS-MODEL for prediction
[22] and 3Drefine for refinement and evaluation [23]. They
were also compared with two-dimensional protein checks
which were done by the GOR IV secondary structure
prediction method [24]. Binding sites of warfarin and
hydroquinone were predicted using VINA [25]. All 12
mutations were inserted into the human VKORC1 protein
sequence since the rodents’ sequences (from Rattus norve-
gicus and Mus musculus) are identical to human VKORC1
at all these positions. Considering the complete VKORC1
protein, mouse and human protein sequences are 92%
homologous (85% identical) whereas rat and human
VKORC1 proteins share 91% homology (83% identity).
Three-dimensional models of wild-type and mutated VK
ORC1 variants were displayed using UCSF Chimera [26].
Results and discussion
Twelve VKORC1 variants which were detected in warfarin-
resistant rats and mice in previous studies [14,15,18,19]
were coexpressed with the coagulation factor FIX in
mammalian cells (Table 1). Culture supernatants were
collected and concentrated and FIX specific activities were
determined based on the whole protein amounts of each
sample assuming a linear relation of the amount of
secreted FIX to the total protein content. For each vari-
ant, transfections and hence, FIX measurements were
performed at least four times and mean values were
calculated. Figure 1 shows the specific activities of FIX
coexpressed with wild-type VKORC1 and the twelve
VKORC1 variants, respectively. In the absence of war-
farin, all variants showed approximately the same or
even higher basal FIX activities compared to the wild-
type and most variants appeared to be insensitive to all
four warfarin concentrations tested. Three variants
(Arg12Trp, Arg61Leu and Glu67Lys) showed specific
activities only slightly higher than the wild-type in the
presence of the two highest warfarin concentrations
(0.1 and 0.3 μM final conc.). Two of these variants
(Arg12Trp and Arg61Leu) were detected in Mus mus-
culus domesticus and most likely originate from Mus
spretus as described above. It is assumed that a gen-
omic region of >10 Mb containing at least four of ten
non-synonymous vkorc1 SNPs was introgressed in the
house mouse from Mus spretus conferring warfarin
resistance [18]. Probably, each of these variants alone
shows only minor warfarin resistance and only a com-
bination of some of these variants causes distinct resist-
ance. While in wild animals the genetic background
may modulate the effect of vkorc1 variants, for our
in vitro studies we chose a homologous system (human
VKORC1 cDNA in the human-derived cell line HEK293) in order to study the variants independently from
such epistatic effects.
When comparing the results of the present study to
the previous data of the DTT-driven VKOR assay [14,15],
the cell culture-based coexpression data show distinct
resistance against warfarin not only for VKORC1 variants
at position 139 but also for variants Ser56Pro, Trp59Arg,
Phe63Cys, Leu120Gln and those concerning Leu128.
Some of these amino acid positions have not only been
shown to be involved in warfarin resistance in rodents
but are also found mutated in humans with elevated
oral anticoagulant dosage requirements or complete resist-
ance against coumarin-type anticoagulants: e.g. Ser56Phe
(4-5x of normal anticoagulant dosage), Trp59Cys (3-4x
of normal dosage), Trp59Leu (4-5x of normal dosage),
Leu128Arg (4-5x of normal dosage) and Tyr139His (3-4x
of normal dosage) [5,17]. Hence, the coexpression assay
seems to reflect the in vivo observed ‘resistance condi-
tions’ much more accurate than the DTT-driven VKOR
assay, independently of the species in which those
VKORC1 mutations were originally detected.
Three-dimensional modelling of all 12 VKORC1 muta-
tions predicted side chain clashes for Arg12Trp, Ser56-
Pro and Phe63Cys. The strongest modifications of side
chains for ligand binding are indicated for Trp59Arg
and Leu120Gln while only small effects are predicted for
Arg61Leu and Glu67Lys (Table 1). This is in good accord-
ance with our experimental data (Figure 1A) in which the
latter two variants show only slight insensitivity to warfarin.
Our results support the idea of Rapoport’s working
group [21] that the sensitivity of VKORC1 to inhibition by
warfarin is not only mediated by the proposed TYA bind-
ing motif (Thr138-Tyr139-Ala140) which was previously
studied by our working group using site-directed muta-
genesis [27], but that other positions play an essential role
as well. According to the published crystal structure of
a bacterial VKOR homolog by Li et al. [21] it is most
likely that the core of VKOR of all species (including those
of mammals) consists of four transmembrane domains
(TMs) bringing together on the luminal side of the ER
membrane all amino acids which are important for en-
zyme activity. Figure 2 shows the VKORC1 mutations
studied here projected into the in silico 3D model
based on the bacterial VKOR structure (Figure 2A) and
the modified VKOR membrane topology model with
the essential four-helix bundle previously published by
Li et al. (Figure 2B) [21]. The luminal loop between
TM1 and TM2 contains a so-called ½ helix which
forms a lid on the four-helix bundle. This “binding
pocket” is large enough to embed one of the ligands:
ubiquinone, vitamin K or coumarin derivatives like
warfarin. Except for Arg12Trp, all eleven mutations of
the present study map close to the binding site of the
ligands as suggested by the 3D and topology models:
Table 1 Overview of the 12 examined VKORC1 variants detected in mice and rats
Mutation Species/ref. 2D, 3D prediction 3D modelling
Arg12Trp Mus musculus, Mus spretus [15,18] 2D: tendency to random coil
3D: clash of side chain
Ser56Pro Rattus norvegicus [14] 2D: tendency to random coil
3D: clash of side chain, less hydrogen bonds
Trp59Arg Rattus spec. [15,19] 2D: tendency to random coil
3D: change of side chain for ligand
Arg61Leu Mus musculus, Mus spretus [15,18] 2D: tendency to beta strand
3D: no important differences
Phe63Cys Rattus spec. [15,19] 2D: tendency to beta strand
3D: clash of side chain
Glu67Lys Rattus spec. [15,19] 2D, 3D: no important differences
Leu120Gln Rattus norvegicus [14] 2D: conversion of helix to beta strand
3D: missing side chain for ligand binding
Leu128Gln Rattus spec. [14,15,19] 2D: partial conversion of helix to beta strand
3D: no differences, interaction with ligand?
Leu128Ser Mus musculus [14,15] 2D: partial conversion of helix to beta strand
3D: no differences, interaction with ligand?
Tyr139Cys Rattus spec., Mus musculus [14,15,19] 2D: tendency to beta strand
3D: no differences, interaction with ligand?
Tyr139Phe Rattus spec. [14,15,19] 2D, 3D: no differences, interaction with ligand?
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Table 1 Overview of the 12 examined VKORC1 variants detected in mice and rats (Continued)
Tyr139Ser Rattus spec. [14,15,19] 2D: tendency to random coil
3D: no differences, interaction with ligand?
Results of two- and three-dimensional protein structure predictions are given in the third column. Pictures of 3D modelling based on human VKORC1 protein
sequence and the bacterial VKOR structure show the protein parts comprising the respective substitutions. The wild-type protein is displayed in beige, the
mutated protein is overlaid in light blue, side chain clashes are highlighted in red.
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and Phe63 immediately follow the ½ helix, Glu67 is
located at the beginning of TM2, Leu120 at the end of
TM3, Leu128 in the luminal loop between TM3 and
TM4 and finally Tyr139 is part of the TYA warfarin
binding motif in TM4. Mutations concerning amino
acid residues 56-67 might affect the lid of the binding
pocket and mutations 120-139 are supposed to lower the
affinity for warfarin [21]. This hypothesis could explain
the observed clustering of mutations in these two protein
domains and the more pronounced warfarin resistance
conferred by mutations in the C-terminal part of the
protein (Figure 1B). Amino acids 120, 128 and 139 are00
200
400
600
800
1,000
1,200
1,400
0 0.05 0.1 0.15
sp
e
ci
fic
 
ac
tiv
ity
 
[%
/m
g]
warfarin concentrati
00
100
200
300
400
500
600
700
800
900
0 0.05 0.1 0.15
sp
e
ci
fic
 
ac
tiv
ity
 
[%
/m
g]
warfarin concentrati
A)
B)
Figure 1 Specific activities of coagulation factor IX coexpressed with
variants at positions 12, 56, 59, 61, 63 and 67; (B): C-terminal variants
different warfarin concentrations.presumably involved directly in binding of the inhibitor
whereas amino acids in the N-terminal part are probably
only required for directing the ligand into the binding
pocket.
In 2012, Tie et al. published a model for the human
vitamin K epoxide reductase with only three transmem-
brane domains (TMD) [28]. Their model is based on
fluorescence protease protection assays after expression
of VKOR fused to GFP (green fluorescence protein)
which is a hydrophilic protein approximately twice the
size of VKOR. Therefore, GFP when directly linked to
VKOR may have an influence on membrane topology of
its fusion partner. Tie at al. also reported that mutations0.2 0.25 0.3
on [µM]
wild-type
Arg12Trp
Ser56Pro
Trp59Arg
Arg61Leu
Phe63Cys
Glu67Lys
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wild-type
Leu120Gln
Leu128Gln
Leu128Ser
Tyr139Cys
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different VKORC1 variants: wild-type (= 100%) and (A): N-terminal
at positions 120, 128 and 139 in the absence and presence of
R12W
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R61L F63C
E67K
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Figure 2 Three-dimensional and topology models of the vitamin K epoxide reductase. A) In silico 3D model of human vitamin K epoxide
reductase based on the homologous bacterial protein structure (PDB-3KP9; [21]). The four transmembrane helices of the core protein are displayed in
yellow, protein structures which are only present in the bacterial homolog (Trx-like domain, linker and 5th transmembrane domain) are shown in grey,
imprecise regions in the human and bacterial protein structure are highlighted in red, positions of the 12 examined substitutions are represented in
blue. The bound substrate (ubiquinone) is shown in white. The location of the interaction partner was verified for vitamin K1 within the human model
using VINA [25] and found to be equivalent. B) Membrane topology model of the vitamin K epoxide reductase according to Li et al. [21] with the
location of the 12 warfarin-resistant mutations examined in this study (red dots).
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from three- to four-TMDs and that both variants are enzy-
matically active [28]. In performing our in silico 2D and
3D modelling of the human enzyme on basis of the bac-
terial homolog we also observed that both topologies are
possible and are easily being converted into each other. In
silico, a single substitution is sufficient to convert the
three-TMD topology model into the four-TMD model
and vice versa. This is further supported by the fact that
membrane topology predictions of VKORs from different
species using different prediction tools sometimes show
the three- and sometimes the four-TMD topology depend-
ing on the software used. Upon crystallisation, the protein
is “frozen” in a state of low energy requirement while
modelling tools suggest that the native enzyme may be
topologically more flexible. It would be conceivable that
the membrane topology is either tissue-specific or that
shifting between the three- and the four-TMD conform-
ation of the vitamin K epoxide reductase is part of its
reaction mechanism: the conformational transition could
impact on opening and closing the lid of the binding
pocket by a kind of flip-flop mechanism which could also
be dependent on the ligand embedded in the pocket – ei-
ther the substrate (vitamin K) or the inhibitor (warfarin).
Conclusions
In conclusion, the cell-based FIX/VKORC1 coexpression
assay measures VKOR activity indirectly via the activity
of carboxylated FIX. This seems to reflect the physio-
logical conditions of the vitamin K metabolism and itswarfarin sensitivity more accurately than the conventional
assay which measures VKOR activity directly in the
presence of the non-physiological strong reductant DTT.
Using this assay, we determined VKOR activities and war-
farin sensitivities of 12 VKORC1 variants reported from
acquired or naturally warfarin-resistant rodents. In con-
trast to the traditional enzyme assay, all variants displayed
strong activities in the absence of anticoagulants and high
to complete insensitivity towards warfarin. In addition,
when these variants were modelled in silico onto the
three-dimensional protein structure of VKOR from Syne-
chococcus sp., all but one variant affected protein domains
suggested relevant for ligand binding by previous studies.Competing interests
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